Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction

Massey, Edwin; Paulus, Ulrike; Dorée, Carolyn; Stanworth, Simon

doi:10.1002/14651858.cd005341.pub2

Cited by 45 publications

(64 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clearly, this was easier to achieve in a pediatric as opposed to an adult population. The ANC increment correlated with the granulocyte dose, reported in previous studies, [2][3][4]11,13,18 and emphasizes the importance of achieving an optimal granulocyte collection.…”

Section: Discussionmentioning

confidence: 69%

“…3,5,6,9,12 The timing and rate of GTs had a role, with early and more frequent administration of GTs leading to improved outcomes. 13,14 One of the significant drawbacks in early studies was the significant side effects observed in recipients. Some studies have confirmed the decreased risk of adverse reactions and increased efficacy of GTs partially matched for HLA antigens and ABO groups.…”

Section: Introductionmentioning

confidence: 99%

“…A Cochrane review in 2009 by Massey et al 13 concluded that higher doses of prophylactic GTs reduced the risk of mortality from infection. Adkins et al 15,17 demonstrated some clinical benefits from prophylactic GTs if given daily and when no leukocyte antibodies were present in the recipients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Nikolajeva

Mijović

Hess

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Bacterial and fungal infections remain a significant cause of transplant-related mortality following allogeneic stem cell transplantation (SCT). Granulocyte transfusions (GTs) may reduce the neutropenic period after SCT and prevent further progression of the existing infection (that is, therapeutic GT) in addition to standard antibacterial and antifungal therapy. A retrospective analysis was performed on 28 consecutive pediatric SCT recipients who received at least one dose of GT between March 2003 and November 2013 at a single institution. All donors were conditioned with G-CSF+dexamethasone with harvest performed 12-18 h later. Indications for SCT were acute leukemia in 46% (13/28) and severe aplastic anemia in 21% (6/28). The main indications for GT were invasive fungal disease in 50%, bacterial infection in 21% and co-morbidities with predicted reduced tolerance to sepsis in 18% (5/28). The median number of GT was 6 (range 1-14) with a median dose of 3.56 × 10 10 granulocytes infused. The median increment in ANC was 1.06 × 10 9 /L and correlated with the granulocyte dose infused. Adverse reactions observed were mild and infrequent. Sixty-four percent of patients (18/28) are alive with only 2 of the 10 deaths being related to progression of infection. In addition there was a low overall incidence of grade 3-4 acute mucositis and a very low incidence (7%) of acute GvHD grade 3-4. Single-donor GTs afford protection to children undergoing SCT at additional risk of infection and may reduce the overall incidence of severe GvHD.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Nikolajeva

Mijović

Hess

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Granulocyte transfusions have also been utilized in the prevention/ prophylaxis setting for immunosuppressed leukemia patients, where responses have been mixed. A Cochrane Review in 2009 of 10 randomized prospective trials failed to demonstrate clinical benefit; notably the majority of included studies featured inadequate PMN doses (<10 10 ) per transfusion; and in the seven studies with adequate granulocytes transfused, mortality was reduced by 60% [18].…”

Section: Introductionmentioning

confidence: 99%

Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy

Aung¹,

DiNardo²,

Martínez³

et al. 2017

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

“…Doses of $1 3 10 9 granulocytes/kg body weight in daily transfusions seem to be required to treat or prevent infection. 9 This dose requirement is difficult to achieve when heavier patients are treated because the usual level of granulocytes collected ranges from 10 to 70 3 10 9 granulocytes per transfusion.…”

mentioning

confidence: 99%

Granulocyte transfusion: questions remain

Cancelas

2015

Blood

View full text Add to dashboard Cite

Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction

Cited by 45 publications

References 41 publications

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy

Granulocyte transfusion: questions remain

Contact Info

Product

Resources

About